Back to Newsroom

Novavax Announces Ebola Vaccine Development Program at the 8th Vaccine and ISV Conference in Philadelphia

Gaithersburg, MD (October 27, 2014) – Novavax, Inc. (NASDAQ: NVAX) today announced that Gale Smith, Ph.D., Vice President of Vaccine Development at Novavax, presented at the 8th Vaccine and ISV Conference in Philadelphia on Sunday, October 26. Dr. Smith’s presentation was titled: 2014 Guinea Ebola Virus Recombinant Glycoprotein (GP) Nanoparticle Vaccine was Highly Immunogenic and Cross-Neutralized 1976 Virus GP Pseudovirus.

Click here to read more